Pharmaceutical University. All the sera were collected in the morning after fasting for more than 9 h when the informed consent was obtained at the University hospital and other related hospitals. The sera from the patients with diseases were collected before surgical or drug treatment. The features of the subjects in this study are shown in Table 1 . The control (Ctrl) group was composed of healthy students (nϭ33) and researchers without diseases (nϭ10). The miscellaneous group (Misc) (nϭ49) included the patients without diseases in the lesion of liver parenchyma, including fatty liver, hepatic hemangioma, gallbladder polyps, gastric cancer, malignant melanoma, diabetes mellitus, hypertension, angina pectoris, congestive heart failure, apoplexie, transient ischemic attack, and bronchitis.
Measurement of MT Levels Serum MT levels were determined by an enzyme-linked immunosorbent assay (ELISA) 25) after acid (1 M HCl) and heat (100°C, 10 min) treatments to eliminate the coexistent antibody-reactive protein. In brief, 10 mg of standard MT-I was dissolved in 10 ml of phosphate buffered saline (PBS) containing 1% 2-mercaptoethanol, and the resulting solution was diluted 10 times with 0.1% carbonate buffer (pH 9.6). Each well containing 100 ml of standard MT-I solution in a 96-well microtiter plate was incubated for 1 h at 37°C and washed three times with PBS containing 0.05% Tween 20 (PBS-T). Each well was blocked with 180 ml of 1% bovine serum albumin (BSA) in PBS-T for 30 min at room temperature and washed three times with PBS-T. An acid (1 M HCl)-and heat-treated sample to be tested and primary antibody were added to each well and incubated for 3 h at room temperature, then washed three times with PBS-T. Each well was incubated with 100 ml of secondary antibody conjugated with horseradish peroxidase for 30 min at room temperature and washed three times with PBS-T. Next, 50 ml of TMB solution, as a substrate for horseradish peroxidase, was added to each well. After sufficient color development, 50 ml of 1 M HCl was added, and the absorbance at 490 nm was measured. The range of the calibration curve was 0.313-40 ng MT/ml, with the correlation coefficient for the calibration curve being rϾ0.99 for a total of five MT concentrations.
Measurement of Metal Levels Serum metal levels were determined by ICP-MS. In brief, 300 ml of sera were heated at 200°C with 60% HNO 3 , 30% H 2 O 2 , and 60% HClO 4 in 50-ml beakers. When the residue became white, the dried samples were dissolved in 10 ml of 6% HNO 3 . Then the metal levels were measured by ICP-MS (ICPM-8500, Shimadzu, Japan). Cu and Zn levels were calculated using calibration curves at a concentration range of 5-500 ppb for each metal. The detection limits of each metal were approximately 0.2 ppb for Cu and 2 ppb for Zn concentrations. The correlation coefficients of linear regression for Cu and Zn were rϾ0.999 for a total of five metal concentrations. Plasma conditions were as follows: coolant gas-flow, plasma gasflow and carrier gas-flow rates were 7.0, 1.5, and 0.6 l/min, respectively, and the sampling depth was 6 mm.
Multivariate Discriminant Analysis Multivariate discriminant analysis (MDA) was carried out by using the Mahalanobis distance (MD 2 ). 26) MD 2 is defined as the weighted distance between an unknown data vector and the mean data vector for a known class of samples. The MD 2 was calculated as follows:
where T is the transposition operator, and S Ϫ1 is the inverse of the variance-covariance matrix. 
group, MDA 2 ; [HCC] group). Others All purified water was manufactured using Elix 5 and Milli Q Laboratory Water Purification Systems (Millipore Co., Bedford, MA, U.S.A.).
Statistics All experiments were repeated in triplicate, and the data are expressed as the meansϮstandard deviations (S.D.). The statistical significance of differences between the groups was evaluated using the Mann-Whitney U-test. 27 ) p values Ͻ0.05 were considered to be statistically significant.
RESULTS
A total of 147 human sera samples (Table 1) were collected, and the MT, Cu, and Zn levels were measured. The resulting serum MT, metal levels, Cu/Zn ratio, and (Cu/Zn)/MT ratio are shown in Fig. 1 . Mean serum MT levels of the patients with Misc and CH did not different from those of the Ctrl; in contrast, serum MT levels of the patients with LC and HCC were lower than those of the Ctrl, Misc, and CH (Fig. 1) . Serum Cu levels of the Ctrl and CH patients were significantly lower than those of the Misc, LC, and HCC patients (Fig. 1) . In contrast, serum Zn levels of the Ctrl were the highest of all subjects, and those of the LC were higher than those of the Misc, CH, and HCC patients (Fig. 1) .
The serum Cu/Zn ratio of the Ctrl was the lowest, and that of the HCC was the highest among all subjects (Fig. 1) . From the Cu/Zn ratio, it was not possible to distinguish between patients with CH, LC, and HCC, so a new parameter, (Cu/Zn)/MT, was introduced. As seen in Fig. 1 , the (Cu/Zn)/MT ratio was found to be sensitive to differences between two groups, namely, the [CtrlϩMiscϩCH] and [LCϩHCC] groups. It could distinguish between the two groups with high accuracy when the threshold was set at 2.60 mM
Ϫ1
. If the (Cu/Zn)/MT ratio is higher than 2.60 mM Ϫ1 , our results indicate that the patient should probably be included in the [LCϩHCC] group (Fig. 2) . As such 88.6% (ϭ31/(31ϩ4)) of the patients with HCC and LC were classified as members of the [LCϩHCC] group based on the (Cu/Zn)/MT ratio. On the basis of the results using (Cu/Zn)/MT, it might be possible to diagnose the pathophysiological change from CH to LC. However, discrimination between patients with LC and HCC was difficult even when using both the Cu/Zn and (Cu/Zn)/MT ratios, as the differences between the ratios of LC and HCC patients were quite small (Fig. 1) . Consequently, other discrimination methods were determined to be needed.
After several trials, we found that multivariate discriminant analysis (MDA) 26) is very useful in distinguishing between LC and HCC. We examined whether the MDA can identify differences between the two groups, [ In addition, the MDA analysis was found to have high diagnostic accuracy, as evaluated by other parameters such as sensitivity and specificity. The sensitivity indicates how exactly the parameter predicts the concerned disease by using the equation: sensitivityϭtrue positive fraction/(true positive fraction + false negative fraction). True positive and negative fractions indicate that the classifications based on MDA score correspond with those based on histological techniques, while false positive and negative fractions indicate that the classifications based on MDA score do not correspond with those based on histological techniques, where positive and negative fractions indicate the number of patients for whom the MDA score is Ͼ0 (positive) and Ͻ0 (negative), respectively. The sensitivity for the MDA 1 and MDA 2 functions were calculated to be 0.857 (ϭ30/(30ϩ5)) and 0.792 (ϭ19/(19ϩ5)), respectively. In contrast, the specificity indicates how exactly the parameter predicts the patients without the concerned disease [specificityϭtrue negative fraction/(true negative fractionϩfalse positive fraction)]. The specificities for the MDA 1 and MDA 2 functions were calculated to be 0.884 (ϭ99/(99ϩ13)) and 0.935 (ϭ115/ (115ϩ8)), respectively.
The results suggest that the MDA 1 and MDA 2 functions were able to discriminate between the hepatic disorders examined. Then, to examine the MDA functions in detail, we combined the MDA 1 (Figs. 3A, B) . By using both MDA scores, the sensitivities for HCC and LC were calculated to be 0.791 (ϭ19/(19ϩ3ϩ2)) and 0.636 (ϭ7/(7ϩ1ϩ3)), respectively, and the specificity was calculated to be 0.884 (ϭ99/(99ϩ7ϩ6)).
Based on the results, serum MT, Cu, and Zn levels and the subsequently obtained MDA scores were found to distinguish between the CH, LC, and HCC hepatic disorders.
DISCUSSION
Many researchers have reported that the serum Cu/Zn ratio is sensitive enough for the diagnosis of various diseases. [28] [29] [30] [31] In the present study, the serum Cu/Zn ratio of patients with different hepatic diseases (Table 1) was also confirmed to be significantly higher than that of the Ctrl (Fig. 1) . But some patients with congestive heart failure, diabetes mellitus, and hypertension exhibited markedly high Cu/Zn ratios (Cu/Zn ratio Ͼ2.0), indicating that the ratio was not selective for diagnosis of the diseases. In contrast, serum MT levels of patients with LC and HCC were significantly lower than those of other subjects. Thus, we combined the Cu/Zn ratio and MT levels and introduced a new parameter, the (Cu/Zn)/MT 2) . However, the ratio could not distinguish between LC and HCC. Therefore, we attempted to examine more reliable methods and found multivariate discriminant analysis (MDA) based on the Mahalanobis distance to be effective for our purpose.
In general, MDA was often computed by linear MDA. However, the linear MDA was applicable only if the variances of each group to be discriminated were statistically equal. In this study, group variances for discrimination were not statistically equal, and we therefore used the Mahalanobis distance 26) to discriminate between diseases. We calculated 2 MDA functions, MDA 1 groups corresponded to the histologically determined diagnosis. Although the diagnostic accuracy in predicting LC patients was not high, it was considered to be useful in diagnosing the hepatic disorders.
It was thought to be difficult to distinguish between HCC and LC patients by serum biochemical signals, because most of the HCC patients possess LC in their livers. Table 1 shows that serum Cu and MT levels of HCC patients were similar to those of LC patients, but serum Zn levels were different between them. In this study, (Cu/Zn)/MT ratio was less effective to distinguish the difference between HCC and LC group, because high levels of serum Zn found in LC patients were canceled by low levels of serum MT. In contrast, MDA distinguished the difference between HCC and LC by using 3 independent parameters, thus the MDA 2 score was useful to distinguish them.
Castaldo G. et al. have successfully discriminated between HCC and LC using MDA.
32) The MDA score showed a diagnostic sensitivity of 85% for HCC, which was higher than or comparable to that of other diagnose. In our results, 79.2% of HCC patients and 63.6% of LC patients were discriminated from other patients with or without hepatic disorders by using only three parameters, serum MT, Cu, and Zn levels (Fig. 3) . Although the sensitivities for HCC and LC in our present results were lower than those of Castaldo et al., our MDA scores could discriminate between HCC, LC and CH patients.
The reported serum MT levels have varied among researchers. [33] [34] [35] [36] [37] The reason for these differences might relate to the specificity of the antibody used. Determination of the serum protein by immunoassay is often involved in differences among results due to cross-reactions with other proteins. The monoclonal antibody used in this study reacted with not only MT-I, but also MT-II. Because some researchers have used MT-I specific antibodies, serum MT levels have been estimated as being relatively low. In the present study, we pretreated the sample with both hydrochloric acid and heat to eliminate the cross-reaction, and quantitated both MT-I and MT-II levels.
On the basis of our present results, we propose here that monitoring of serum MT and metal levels and subsequent MDA analysis are very useful in discriminating between hepatic diseases, providing important information for the evaluation of pathophysiological changes in chronic hepatic disorders. 
